On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its ...

Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and cancer, is in “advanced talks” to be acquired by Germany’s Merck ...

After Merck KGaA's recent confirmation that it's in "advanced discussions" to acquire SpringWorks Therapeutics, the Connecticut rare disease specialist has boosted its value with a new FDA nod.

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...

Merck KGaA reaffirmed its strong performance ... but provided little additional information on ongoing acquisition talks with SpringWorks Therapeutics. Speculation surrounding a potential ...

HC Wainwright reiterated their buy rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX – Free Report) in a report published on Friday,Benzinga reports. They currently have a $74.00 price ...

Also Read: Germany’s Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics NF1 is a genetic disorder affecting approximately 100,000 children and adults in the United States.

A potential acquisition of SpringWorks Therapeutics by Merck KGaA could bring significant benefits to both companies and potentially create substantial value for shareholders: 1. Enhanced resources: ...